← All trials
NCT04536272
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2020
- Primary completion
- Mar 1, 2023
- Completion date
- Mar 1, 2024
- First posted
- Sep 2, 2020
- Last posted
- Oct 19, 2020
- Enrollment
- 330
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of GroningenLead sponsor
- Isala Clinics, Zwolle, The NetherlandsCollaborator
- St. Antonius Hospital, NieuwegeinCollaborator
- University of AmsterdamCollaborator
- Erasmus University RotterdamCollaborator
- Leiden UniversityCollaborator
- Radboud UniversityCollaborator
- ZonMw: The Netherlands Organisation for Health Research and DevelopmentCollaborator
- University of GroningenReponsible party - principal investigator
- University of GroningenOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.